Table 3.
Clinical characteristics of liver transplant recipients with HCC by donor sex after PSM
| Variables | Male donor n = 1242 |
Female donor n = 621 |
P value | SMD |
|---|---|---|---|---|
| Donor age | 0.89 | 0.01 | ||
| < 50 y | 718 (57.81%) | 361 (58.13%) | ||
| ≥ 50 y | 524 (42.19%) | 260 (41.87%) | ||
| Recipient sex | 0.14 | 0.07 | ||
| Male | 1061 (85.43%) | 546 (87.92%) | ||
| Female | 181 (14.57%) | 75 (12.08%) | ||
| Donor BMI | 22.8 (20.8–24.5) | 22.2 (20.2–24.7) | 0.38 | 0.05 |
| Donor type | 0.43 | −0.04 | ||
| DBD | 724 (58.29%) | 350 (56.36%) | ||
| DCD | 518 (41.71%) | 271 (43.64%) | ||
| ABO blood incompatibility | 0.51 | 0.03 | ||
| Incompatible | 30 (2.42%) | 12 (1.93%) | ||
| Compatible | 1212 (97.58%) | 609 (98.07%) | ||
| Recipient age | 0.71 | 0.02 | ||
| < 50 y | 495 (39.86%) | 253 (40.74%) | ||
| ≥ 50 y | 747 (60.14%) | 368 (59.26%) | ||
| Hypertension | 0.95 | −0.01 | ||
| No | 1137 (91.55%) | 568 (91.47%) | ||
| Yes | 105 (8.45%) | 53 (8.53%) | ||
| Diabetes | 0.92 | −0.01 | ||
| No | 1100 (88.57%) | 551 (88.73%) | ||
| Yes | 142 (11.43%) | 70 (11.27%) | ||
| HBsAg | 1.00 | 0 | ||
| Negative | 176 (14.17%) | 88 (14.17%) | ||
| Positive | 1066 (85.83%) | 533 (85.83%) | ||
| Child-Pugh classification | 0.74 | −0.02 | ||
| A | 266 (21.42%) | 134 (21.58%) | ||
| B | 480 (38.65%) | 229 (36.88%) | ||
| C | 496 (39.94%) | 258 (41.55%) | ||
| Any TACE | 0.56 | 0.03 | ||
| No | 1045 (84.14%) | 529 (85.19%) | ||
| Yes | 197 (15.86%) | 92 (14.81%) | ||
| Any RFA | 0.78 | −0.01 | ||
| No | 1170 (94.20%) | 583 (93.88%) | ||
| Yes | 72 (5.80%) | 38 (6.12%) | ||
| MELD | 14 (9–28) | 14 (9–30) | 0.67 | −0.02 |
| Beyond Milan criteria | 0.89 | 0.01 | ||
| No | 732 (58.94%) | 243 (58.62%) | ||
| Yes | 510 (41.06%) | 139 (41.38%) | ||
| Beyond Hangzhou criteria | 1.00 | 0 | ||
| No | 1056 (85.02%) | 528 (85.02%) | ||
| Yes | 186 (14.98%) | 93 (14.98%) | ||
| Largest tumor size | 0.83 | 0.01 | ||
| < 3 cm | 474 (38.16%) | 236 (38.00%) | ||
| 3–5 cm | 515 (41.47%) | 265 (42.67%) | ||
| > 5 cm | 253 (20.37%) | 120 (19.32%) | ||
| Tumor number | 0.97 | 2.64 | ||
| Single | 721 (58.05%) | 361 (58.13%) | ||
| Multiple | 521 (41.95%) | 260 (41.87%) | ||
| Microsatellite | 0.64 | 0.03 | ||
| No | 1097 (88.33%) | 553 (89.05%) | ||
| Yes | 145 (11.67%) | 68 (10.95%) | ||
| Cold ischemia time (h) | 6.0 (4.7–8.0) | 6.0 (4.7–8.0) | 0.59 | 0.03 |
| Operative time (h) | 7.2 (6.0–8.3) | 7.0 (6.0–8.3) | 0.50 | 0.05 |
| Operative bleeding (mL) | 900 (500–1500) | 1000 (500–1500) | 0.49 | 0.03 |
| Salvage LT | 0.79 | −0.01 | ||
| No | 1048 (84.38%) | 521 (83.90%) | ||
| Yes | 194 (15.62%) | 100 (16.10%) | ||
| Follow-up time (months) | 29.9 (18.0–42.5) | 28.9 (17.3–41.3) | 0.15 | 0.07 |
PSM, propensity score matching; LT, liver transplantation; BMI, body mass index; MELD, model for end-stage liver disease; CHILD, Child-Pugh; DBD, donation after brain death; DCD, donation after circulatory death; DBCD, donation after brain and cardiac death; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; SMD, standardized mean difference.